Expansion of anti-mesothelin specific CD4+and CD8+ T cell responses in patients with pancreatic carcinoma

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Chen, Yuan ^a   Ayaru, Lakshmana ^b   Mathew, Sanju ^b   Morris, Emma ^a   Pereira, Stephen P ^a   Behboudi, Shahriar ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; INTERLEUKIN 10; MESOTHELIN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MIDDLE AGED; PANCREAS CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEMOGRAPHY; GPI-LINKED PROTEINS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; PEPTIDES;

EID: 84895725055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088133     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
3. Malvezzi M, Arfe A, Bertuccio P, Levi F, La Vecchia C, et al. (2011) European cancer mortality predictions for the year 2011. Ann Oncol 22: 947-956.
4. Maisonneuve P, Lowenfels AB (2010) Epidemiology of pancreatic cancer: an update. Dig Dis 28: 645-656.
5. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB (2008) Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393: 535-545.
6. Jiao L, Berrington de Gonzalez A, Hartge P, Pfeiffer RM, Park Y, et al. (2010) Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control 21: 1305-1314.
7. Bartsch DK, Gress TM, Langer P (2012) Familial pancreatic cancer-current knowledge. Nat Rev Gastroenterol Hepatol 9: 445-453.
8. Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, et al. (2012) Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 23: 2964-2970.
9. Elena JW, Steplowski E, Yu K, Hartge P, Tobias GS, et al. (2013) Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 24: 13-25.
10. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
11. Cress RD, Yin D, Clarke L, Bold R, Holly EA (2006) Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 17: 403-409.
12. O'Reilly EM, Lowery MA (2012) Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. Cancer J 18: 609-613.
13. Bayraktar S, Bayraktar UD, Rocha-Lima CM (2010) Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 16: 673-682.
14. Chua YJ, Zalcberg JR (2008) Pancreatic cancer - is the wall crumbling? Ann Oncol 19: 1224-1230.
15. Vulfovich M, Rocha-Lima C (2008) Novel advances in pancreatic cancer treatment. Expert Rev Anticancer Ther 8: 993-1002.
16. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
17. Finn OJ (2008) Cancer immunology. N Engl J Med 358: 2704-2715.
18. Kennedy R, Celis E (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222: 129-144. (Pubitemid 351430378)
19. Dobrzanski MJ (2013) Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol 3: 63.
20. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, et al. (2010) Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 11: 19.
21. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, et al. (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29: 1949-1955.
22. Herlyn D, Birebent B (1999) Advances in cancer vaccine development. Ann Med 31: 66-78. (Pubitemid 29134487)
23. Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 93: 136-140. (Pubitemid 26041483)
24. Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373-381.
25. Hassan R, Bera T, Pastan I (2004) Mesothelin: a new target for immunotherapy. Clin Cancer Res 10: 3937-3942. (Pubitemid 38812466)
26. Ordonez NG (2003) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16: 192-197.
27. Ordonez NG (2003) Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27: 1418-1428.
28. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, et al. (2005) Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 124: 838-845. (Pubitemid 41740183)
29. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, et al. (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13: 2928-2935. (Pubitemid 46850705)
30. Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, et al. (2006) Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res 26: 4721-4728.
31. Johnston FM, Tan MC, Tan BR, Jr., Porembka MR, Brunt EM, et al. (2009) Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 15: 6511-6518.
32. Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20: 2902-2906. (Pubitemid 30183509)
33. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, et al. (2008) Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 7: 286-296. (Pubitemid 351302523)
34. Zhang S, Yong LK, Li D, Cubas R, Chen C, et al. (2013) Mesothelin Virus-Like Particle Immunization Controls Pancreatic Cancer Growth through CD8(+) T Cell Induction and Reduction in the Frequency of CD4(+)foxp3(+)ICOS(-) Regulatory T Cells. PLoS One 8: e68303.
35. Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, et al. (2004) Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200: 297-306. (Pubitemid 39031249)
36. Hamilton SR AL, eds. (2000) Pathology and Genetics of Tumours of the Digestive System. WHO Classification of Tumours. Lyon: IARC Press.
37. Germano G, Allavena P, Mantovani A (2008) Cytokines as a key component of cancer-related inflammation. Cytokine 43: 374-379.
38. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, et al. (2011) IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 20: 781-796.
39. Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, et al. (2012) IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 72: 3570-3581.
40. Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14: e218-228.
41. Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, et al. (2012) An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas 41: 1001-1007.
42. Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, et al. (2005) Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 11: 6342-6351. (Pubitemid 41262966)
43. Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, et al. (2009) Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137: 682-690.
44. Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, et al. (2008) Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology 48: 1821-1833.
45. Sato K, Tanaka M, Kusaba T, Fukuda H, Tanikawa K (1998) Immunohistochemical demonstration of alpha-fetoprotein in small hepatocellular carcinoma. Oncol Rep 5: 355-358. (Pubitemid 28100088)